Revenue: As of FY2025 Q2, the actual value is USD 119.8 M.

EPS: As of FY2025 Q2, the actual value is USD -0.15.

EBIT: As of FY2025 Q2, the actual value is USD -11.21 M.

Segment Revenue

• Consolidated Revenue: $119.8 million, an increase of 21.5% from $98.6 million in Q2 2024.
• Patient Services Revenue: $55.9 million, up from $52.5 million.
• Dispensary Revenue: $62.6 million, up from $44.4 million.
• Clinical Trials & Other Revenue: $1.3 million, down from $1.7 million.

Operational Metrics

• Gross Profit: $17.5 million, an increase of 34.4%.
• Net Loss: - $17.0 million, compared to - $15.5 million in Q2 2024.
• Adjusted EBITDA: - $4.1 million, compared to - $8.7 million.

Cash Flow

• Cash and Cash Equivalents: $30.3 million as of June 30, 2025.
• Net Cash Used in Operating Activities: - $15.2 million for the six months ended June 30, 2025, compared to - $31.5 million in 2024.
• Free Cash Flow: - $14.6 million, compared to - $31.8 million in 2024.

Unique Metrics

• Fee-for-Service Revenue Growth: 10% over Q2 2024, driven by new markets.
• Retail Pharmacy and Dispensary Contribution: $62.6 million in revenue and over $11 million in gross profit in Q2 2025.

Outlook / Guidance

• The Oncology Institute reaffirms its full-year 2025 guidance with expected revenue between $460 to $480 million and gross profit between $73 to $82 million.
• Adjusted EBITDA is projected to be between - $8 to - $17 million, and Free Cash Flow is expected to be between - $12 to - $21 million.
• The company anticipates reaching the higher end of its revenue guidance range for 2025, with Adjusted EBITDA expected to be approximately - $2.5 to - $3.5 million in Q3 2025.